Antibe Therapeutics Inc. (OTCMKTS:ATBPF – Get Free Report) was the target of a significant increase in short interest in April. As of April 15th, there was short interest totalling 65,100 shares, an increase of 1,934.4% from the March 31st total of 3,200 shares. Based on an average daily volume of 92,600 shares, the days-to-cover ratio is currently 0.7 days.
Antibe Therapeutics Price Performance
Shares of OTCMKTS:ATBPF remained flat at $0.22 on Thursday. Antibe Therapeutics has a twelve month low of $0.11 and a twelve month high of $0.89. The business’s fifty day simple moving average is $0.38 and its 200 day simple moving average is $0.53.
Antibe Therapeutics (OTCMKTS:ATBPF – Get Free Report) last released its quarterly earnings data on Wednesday, February 14th. The company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.03. On average, analysts anticipate that Antibe Therapeutics will post -0.31 EPS for the current year.
Analyst Ratings Changes
Check Out Our Latest Report on ATBPF
Antibe Therapeutics Company Profile
Antibe Therapeutics Inc, a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs).
Featured Stories
- Five stocks we like better than Antibe Therapeutics
- What is a Stock Market Index and How Do You Use Them?
- Hasbro’s Management Made All the Right Calls This Quarter
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower Prices
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Power Surge: Utilities Sector’s Resilience Shines
Receive News & Ratings for Antibe Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antibe Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.